ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Risk Factors for Losing Varicella Immunity after Pediatric Kidney Transplantation

H. Pizzo1, J. Mirocha2, J. Garrison1, P. R. Soni3, S. Nadipuram3, D. Puliyanda1

1Pediatric Nephrology, Cedars-Sinai Medical Center, Los Angeles, CA, 2Biostatistics Core, Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 3Pediatric Infectious Disease, Cedars-Sinai Medical Center, Los Angeles, CA

Meeting: 2020 American Transplant Congress

Abstract number: C-049

Keywords: IgG, Vaccination

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session C: Kidney: Pediatrics

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Use of Subunit Herpes Zoster Vaccine in VZV-Seronegative Transplant Recipients to Prevent Primary Varicella
  • MMR and Varicella Immunity After Pediatric Liver Transplant.

*Purpose: Vaccination against varicella zoster (VZV) pre-kidney transplant (kid tx) can help prevent severe disseminated VZV disease in immunosuppressed patients (pts) post-tx. Despite confirmation of serologic response to vaccinations pre-tx, studies have shown loss of humoral immunity (imm) post-tx. Here we assess risk factors for losing VZV imm after pediatric (ped) kid tx.

*Methods: A retrospective analysis of 44 ped kid tx pts with positive pre-tx VZV IgG (> 0.9 index) was performed. Pts were induced with a lymphocyte depleting (LDA: ATG or alemtuzumab) or non-lymphocyte depleting agent (NLDA: basiliximab or daclizumab) and maintained on mycophenolate mofetil, tacrolimus, with or without steroids. Loss of VZV imm (VZV IgG < 0.9 index) post-tx was evaluated based on 1) induction agent used 2) number of VZV vaccines (vx) received prior to tx 3) interval between last dose of VZV vx and tx 4) if pt received treatment for rejection.

*Results: Median age at tx was 10.8 yrs (1.1-19.5); 25 were male (56.8%); 38 (86.4%) received deceased donor tx; 26 (59%) received LDA; 12 (28.6%) received 1 VZV vx prior to tx; 10 (22.7%) received their last VZV vx ≤ 1 year prior to tx. Loss of VZV imm was 4.7%, 14.2%, and 29.2% at 2, 4 and 8 yrs post-tx, respectively. In a subgroup analysis comparing the induction agent used, loss of imm appeared to occur earlier in the LDA group (Figure 1, p = 0.021). Loss of VZV imm in those who received 1 VZV vx prior to tx was 0%, 9.1%, and 27.3% at 2, 4, and 8 yrs post-tx, respectively, vs. 6.9%, 18.1% and 31.8% in those that received ≥ 2 (p = 0.88). Among those that received their last VZV vx ≤ 1 year prior to tx, loss of VZV imm was 0%, 27.1% and 27.1% at 2, 4, and 8 yrs post-tx, respectively, compared to 6.3%, 10.6%, and 33% in those that received their last VZV vx > 1 yr prior to tx (p = 0.61). Seven of 19 pts who had been treated for rejection lost VZV imm vs. 4 of 25 who did not have rejection (HR = 7.27; 95%CI 1.84-28.77; p = 0.005).

*Conclusions: Ped kid tx pts are at risk for losing VZV imm post-tx, particularly over time. It appears that the loss of imm occurs earlier in those who receive LDA. There was no evidence that the number of VZV vx received prior to tx or the timing between the last VZV vx and tx influences the loss of imm. Receiving treatment for rejection increases the risk for losing VZV imm. Post-tx VZV serologies should be monitored to identify pts at highest risk for disseminated VZV, particularly after treatment for rejection.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Pizzo H, Mirocha J, Garrison J, Soni PR, Nadipuram S, Puliyanda D. Risk Factors for Losing Varicella Immunity after Pediatric Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/risk-factors-for-losing-varicella-immunity-after-pediatric-kidney-transplantation/. Accessed April 18, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.